Skip to main content

Posts tagged with "Cardiovascular Disease"

  • Cardiovascular Disease

    Once More Into the CETP, Friends

    So folks, let’s raise a bunch of money and pile back into CETP! You know, that great cardiovascular target that has been an absolute vale of tears for every big drug company that’s tried to develop it? What do you say? Interestingly enough, someone is doing just that. I wrote last year about DalCor, a Montreal-based… Read More
  • Cardiovascular Disease

    From the Far Corner of the Basement

    To go along with that recent CETP trial news, here’s another one for the “We don’t know much about human lipid handing” file. A dietary study originally done back in the 1960s and 1970s has been (almost literally) resurrected, with data pulled out of yellowing stacks of paper, old cardboard boxes, and ancient-format computer… Read More
  • Cardiovascular Disease

    CETP Finally Heads to the Trash Heap?

    The tale of CETP (cholesteryl ester transfer protein) as a drug target has been long, and convoluted, and expensive, and horrendously disappointing. Pfizer failed, Roche failed, several other companies like BMS who didn’t even get that far failed, and last fall Lilly’s entry failed, too (that link has links to several past blog posts he… Read More
  • Cardiovascular Disease

    Up to Speed on Meldonium

    I will freely admit that I had never heard of meldonium (aka mildronate) until yesterday, when it made headlines across the sports pages (and cost Maria Sharapova a great deal of endorsement money). That’s probably because it’s never been approved in the US or anywhere in Western Europe. That category of drugs is a relatively small an… Read More
  • Business and Markets

    What a Brief Regeneron Panic Tells Us

    Matthew Herper has a good article on a recent (and fortunately short) scare for Regeneron. Several investors had used the Freedom of Information Act to get FDA adverse-event reporting on the PCSK9 drugs, and this made it look as if Regeneron’s Praluent (alirocumab) was associated with several suicides, while Amgen’s Repatha (evolocumab) Read More
  • Cardiovascular Disease

    Onward With CETP!

    Merck is damning the torpedoes and going ahead with its CETP program. A committee has reviewed the data so far for futility, and recommended no changes, so (as FierceBiotech says), they’re pretty much locked in now for the rest of the study, which finishes up in 2017. A mere 30,000 patients (!) are involved, which… Read More
  • Cardiovascular Disease

    A Low-Cholesterol Vaccination?

    We have dueling PCSK9 antibodies on the market – Praluent (alirocumab) and Repatha (evolocumab) – and they’re both out there lowering LDL levels as we speak. (Whether these have the desired long-term outcomes remains to be seen; there’s no other way to find out than to wait and watch). But there’s another approach to t… Read More
  • Cardiovascular Disease

    CETP Failure: Now It’s Lilly’s Turn

    It’s been a while since CETP came up on this site as a drug target. This has been many companies’ best shot at an HDL-raising therapy, to go along with the LDL-lowering effects of the statins (and now the PCSK9 inhibitors). The prospect of a two-front attack on cardiovascular disease (and the cardiovascular disease market) Read More
  • Alzheimer's Disease

    Prions In the News (Unfortunately)

    Let’s talk about proteins for a few minutes – nasty, unfriendly proteins, of the sort that will ball up and crash out of solution the first chance they get. Anyone working in a protein purification lab will have encountered plenty of these, and will be familiar with the various tricks available to keep things in… Read More
  • Cardiovascular Disease

    PCSK9 In the Details

    The PCSK9 inhibitors are a class of drugs from which great things are expected. The first ones hitting the market are antibodies, and blocking this enzyme, which is involved in cholesterol homeostasis, clearly has major effects on circulating LDL levels. There are a lot of approaches to going after this target, in the lab, the… Read More